Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDP225 in chronic functional vomiting
NCT00252993Phase 2Terminated
- Sponsor
- Dynogen Pharmaceuticals, Inc.
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DDP-225 in Functional Vomiting (FV) and cyclic vomiting syndrome (CVS) (3 arms), sponsored by Dynogen Pharmaceuticals, Inc. Primary endpoint: Frequency and intensity of nausea and vomiting episodes at 12 weeks. Started Nov 2005; status: terminated.
02
Drugs
DDP-225
03
Conditions
Functional Vomiting (FV)cyclic vomiting syndrome (CVS)
Beyond the preview
Go deeper on NCT00252993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252993.